This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 50 three times a day to biphasic insulin aspart 70 three times a day in non-obese and obese with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
75
Novo Nordisk Investigational Site
Århus C, Denmark
Area under the serum glucose concentration profile during 24 hours
Time frame: after 4 weeks of treatment
Pharmacodynamics properties
Pharmacokinetic properties
8-point self-monitored blood glucose profiles
Adverse events
Hypoglycaemic episodes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.